Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
| Status: | Completed |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 1/7/2017 |
| Start Date: | April 2006 |
| End Date: | July 2007 |
Effects of NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) BID and QD vs. Byetta™ Exenatide) BID on Glycemic Control: A Multicenter, 24-Week, Open-Label, Parallel Group Study in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets With Metformin and a Sulfonylurea
This trial is conducted in the United States of America (USA). The study will compare A1C
reduction achieved in patients receiving biphasic insulin aspart 70/30 once or twice daily
to patients receiving exenatide twice daily. Patients enrolled in the study will be insulin
naive patients who have not achieved glycemic control with metformin and sulfonylurea.
reduction achieved in patients receiving biphasic insulin aspart 70/30 once or twice daily
to patients receiving exenatide twice daily. Patients enrolled in the study will be insulin
naive patients who have not achieved glycemic control with metformin and sulfonylurea.
Inclusion Criteria:
- Type 2 diabetes
- HbA1C: At least 8%
- Patients that were never treated with insulin before
- Current therapy with metformin and a sulfonylurea.
Exclusion Criteria:
- History of recurrent, severe hypoglycemia
- Hepatic insufficiency: ALT, AST or alkaline phosphatase > 2.5 times upper limits of
laboratory's normal
- Renal insufficiency: serum creatinine > 1.3 mg/dL (males) or > 1.2 mg/dL (females)
- Severe gastrointestinal disease, including gastroparesis
We found this trial at
1
site
Click here to add this to my saved trials
